NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers. In Vitro NSC745885 (0.5-4 μM; 24, 48 or 72 hours) has a growth inhibitory or death-promoting effect on the SAS cells, it significantly decreases the\ndensities of cultured cells when compared with untreated cells. The IC 50 of NSC745885 is 0.85 μM after 72 hours’ treatment. NSC745885 (0.5-4 μM; 24 hours) increases annexin V positive cells in a dose-dependent manner, and the differences appears as a dose-dependent manner. NSC745885 (0.5-2 μM; 24 or 48 hours) decreases XIAP protein levels and increases protein levels both as a dose-dependent manner in SAS cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: SAS cells is obtained from a poorly differentiated human squamous cell carcinoma Concentration: 0.5 μM, 1 μM, 1.5 μM, 2 μM, 4 μM Incubation Time: 24, 48, or 72 hours Result: Decreases SAS cells growth as a time and dose-dependent manner. Apoptosis AnalysisCell Line: SAS cells is obtained from a poorly differentiated human squamous cell carcinoma Concentration: 0.5 μM, 1 μM, 1.5 μM, 2 μM, 4 μM Incubation Time: 24 hours Result: Decreases SAS cells growth as a time and dose-dependent manner. Western Blot AnalysisCell Line: SAS cells is obtained from a poorly differentiated human squamous cell carcinoma Concentration: 0.5 μM, 1 μM, 1.5 μM, 2 μM Incubation Time: 24 or 48 hours Result: Increased cleaved caspase-3 expression and decreased XIAP expression. In Vivo NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Eight-week-old NOD/SCID (NOD.CB17 Prkdc scid /J) mice Dosage: 2 mg/kg Administration: Intraperitoneal injection; 2 mg/kg; once daily; 10 days Result: Inhibited engrafted tumors growth in vivo. Form:Solid